Circassia

Circassia is a world-class specialty biopharmaceutical business focused on allergy and respiratory disease. The Company has an established commercial infrastructure, marketed products, a pipeline of near-term therapies and a portfolio of next generation treatments targeting multi-$billion market opportunities. Circassia sells its novel, market-leading products for asthma management directly to allergy / asthma specialists in the United States and Germany. Its products are also promoted in a number of other countries by the Company’s international network of partners.
Circassia’s broad-based development pipeline includes a range of treatments for allergy and respiratory disease. Circassia’s most advanced next-generation immunotherapy is currently in phase III testing for cat allergy, and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia’s lead asthma product targets substitution of GSK’s FLIXOTIDE® pMDI, and UK approval is expected in December 2015. Circassia anticipates two further product filings in 2016, targeting direct substitution of SERETIDE® pMDI and SEREVENT® pMDI. The Company is also developing a number of novel treatments, including a fixed dose ‘triple’ combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

Type
Public
HQ
Oxford, GB
Founded
2006
Employees
204 (est)+224%
Circassia was founded in 2006 and is headquartered in Oxford, GB

Key People at Circassia

Steven Harris

Steven Harris

CEO
Charles Swingland

Charles Swingland

Deputy Chairman and General Counsel

Circassia Locations

Oxford, GB
Chicago, US
Solna, SE

Circassia Metrics

Circassia Summary

Market capitalization

£258 M

Closing share price

£0.88
Circassia's latest market capitalization is £258 M.

Circassia Market Value History

Circassia News

Circassia Company Life

You may also be interested in